CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data

Anwar, Muhammad Yasir; Williams, Grant R.; Paluri, Ravi Kumar

doi:10.1007/s12029-020-00457-1

Cited by 16 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This type of therapy is mainly used in patients with refractory or resistant hematological malignancies such as B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). Nowadays, there are more and more attempts to use CAR-T cells to fight solid tumors [ 144 , 145 , 146 , 147 ].…”

Section: Chimeric Antigen Receptor T Cell (Car-t Cell) Therapymentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

Modern oncological therapy utilizes various types of immunotherapy. Immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cells (CAR-T) therapy, cancer vaccines, tumor-targeting monoclonal antibodies (TT-mAbs), bispecific antibodies and cytokine therapy improve patients’ outcomes. However, stimulation of the immune system, beneficial in terms of fighting against cancer, generates the risk of harm to other cells in a patient’s body. Kidney damage belongs to the relatively rare adverse events (AEs). Best described, but still, superficially, are renal AEs in patients treated with ICIs. International guidelines issued by the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) cover the management of immune-related adverse events (irAEs) during ICI therapy. There are fewer data concerning real occurrence and possible presentations of renal adverse drug reactions of other immunotherapeutic methods. This implies the need for the collection of safety data during ongoing clinical trials and in the real-life world to characterize the hazard related to the use of new immunotherapies and management of irAEs.

show abstract

Section: Chimeric Antigen Receptor T Cell (Car-t Cell) Therapymentioning

confidence: 99%

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Borówka

Łącki-Zynzeling

Nicze

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…A number of clinical trials are now underway, intending to define the usage of this therapeutic technique in the near future. Mesothelin, CD133, PSCA, claudin 18.2, EGFR, CEA, MUC1, and HER2 were among the antigens targeted for therapy in these studies [ 165 , 167 , 168 ]. Mesothelin appears to be the most potential CAR target due to its high expression levels, particularly in mesothelioma, pancreatic, and OC [ 169 ].…”

Section: Car-modified Immune Cells In Solid Tumorsmentioning

confidence: 99%

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

et al. 2022

View full text Add to dashboard Cite

Advancements in adoptive cell therapy over the last four decades have revealed various new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated immune cells that are engineered and administered to eliminate cancer cells. In this context, CAR T-cells have shown significant promise in the treatment of hematological malignancies. However, many obstacles limit the efficacy of CAR T-cell therapy in both solid tumors and hematological malignancies. Consequently, CAR-NK and CAR-M cell therapies have recently emerged as novel therapeutic options for addressing the challenges associated with CAR T-cell therapies. Currently, many CAR immune cell trials are underway in various human malignancies around the world to improve antitumor activity and reduce the toxicity of CAR immune cell therapy. This review will describe the comprehensive literature of recent findings on CAR immune cell therapy in a wide range of human malignancies, as well as the challenges that have emerged in recent years.

show abstract

“…The biological functions of Msln have been poorly understood because Msln-deficient mice do not show a detectable phenotype under physiological conditions [ 62 ]. On the other hand, Msln is known to be highly expressed in several human tumors including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocyte carcinoma [ 63 , 64 , 65 ], and thus it has attracted attention as a potential target for anti-cancer therapy [ 61 , 66 ] by newly developed strategies of immunotherapy using recombinant immunotoxin, antibody-drug conjugates, chimeric monoclonal antibody, and chimeric antigen receptor T cell therapy [ 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ]. Msln expression is abundant in normal mesothelial cells, which are major components of the mesothelial layer lining parenchymal organs and serosal cavities [ 62 ].…”

Section: Biological Function Of Mesothelin Muc16 and Thy1mentioning

confidence: 99%

The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury

Nishio

Koyama

Fuji

et al. 2022

Biology

View full text Add to dashboard Cite

Fibrosis is a common consequence of abnormal wound healing, which is characterized by infiltration of myofibroblasts and formation of fibrous scar. In liver fibrosis, activated Hepatic Stellate Cells (aHSCs) and activated Portal Fibroblasts (aPFs) are the major contributors to the origin of hepatic myofibroblasts. aPFs are significantly involved in the pathogenesis of cholestatic fibrosis, suggesting that aPFs may be a primary target for anti-fibrotic therapy in cholestatic injury. aPFs are distinguishable from aHSCs by specific markers including mesothelin (Msln), Mucin 16 (Muc16), and Thymus cell antigen 1 (Thy1, CD90) as well as fibulin 2, elastin, Gremlin 1, ecto-ATPase nucleoside triphosphate diphosphohydrolase 2. Msln plays a critical role in activation of PFs, via formation of Msln-Muc16-Thy1 complex that regulates TGFβ1/TGFβRI-mediated fibrogenic signaling. The opposing pro- and anti-fibrogenic effects of Msln and Thy1 are key components of the TGFβ1-induced activation pathway in aPFs. In addition, aPFs and activated lung and kidney fibroblasts share similarities across different organs with expression of common markers and activation cascade including Msln-Thy1 interaction. Here, we summarize the potential function of Msln in activation of PFs and development of cholestatic fibrosis, offering a novel perspective for anti-fibrotic therapy targeting Msln.

show abstract

CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data

Cited by 16 publications

References 72 publications

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Adverse Renal Effects of Anticancer Immunotherapy: A Review

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

The Role of Mesothelin in Activation of Portal Fibroblasts in Cholestatic Liver Injury

Contact Info

Product

Resources

About